Telemedicine To Help Vivos Therapeutics Expand Into Orofacial Myofunctional Therapy

Vivos Therapeutics, Inc., is taking yet another step in becoming an impact player in the growing need to help people suffering from sleep disorders.

The medical technology company, focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), just announced that it will launch a new service called MyoCorrect, where trained therapists will provide Vivos-trained providers access to orofacial myofunctional therapy (OMT) via telemedicine technology as a component to OSA treatment using the Company’s Vivos System.

Related Reading: A New Approach to Sleep-Disordered Breathing

Vivos expects to see additional revenue from its new MyoCorrect service in the form of increased Vivos System cases and fees charged for the service. The company believes the MyoCorrect service will become an important value-added component in the treatment of OSA using the Vivos System. Further the company believes that offering OMT as a service will provide it with an additional competitive advantage in the OSA treatment marketplace.

OMT therapists work to strengthen and improve function in the muscles of the lips, tongue, cheeks and face and their related roles in breathing, sucking, chewing, swallowing, and some aspects of speech. Research has shown OMT to be an effective component of OSA treatment. Vivos plans to make the MyoCorrect protocol available as a component of their system and will actively integrate training and implementation protocols for Vivos-trained dentists to utilize the MyoCorrect therapy.

According to the company, Vivos-trained dentists who have actively incorporated OMT into their Vivos System treatment protocols report 4 primary benefits: (1) higher case acceptance, (2) better patient compliance, (3) shorter treatment times, and (4) improved clinical outcomes. However, due to scarcity of trained OMT therapists in many areas and other factors, too few dentists and patients have been able to access this important adjunctive therapy. MyoCorrect will provide every Vivos dentist with immediate and easy access via telemedicine to this valuable clinical resource at an attractive price point.

“We believe this clinical enhancement to our flagship Vivos System treatment for mild-to-moderate OSA will work synergistically within the emerging Vivos dental sleep medicine ecosystem. This ecosystem features extensive clinical training through the Institute for Craniofacial Sleep Medicine, Vivos AireO2 practice management software, Vivos Airway Intelligence Services, Vivos Billing Intelligence Services, VivoScore diagnostic devices powered by SleepImage, our proprietary Vivos System oral appliance therapy, and multidisciplinary collaboration between physicians and Vivos dentists through the growing network of Vivos-trained dentist offices and Pneusomnia clinics,” Vivos’ Chairman and CEO Kirk Huntsman says.

The launch of MyoCorrect follows the acquisition by Vivos of certain assets from and the entry into related agreements with MyoCorrect, LLC and its affiliates. MyoCorrect, LLC is a healthcare provider based in New York that specializes in the delivery of OMT via telemedicine.